×
Vericel Net Current Debt 2010-2025 | VCEL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Vericel net current debt from 2010 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
Vericel Net Current Debt 2010-2025 | VCEL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Vericel net current debt from 2010 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$226.4B
Amgen (AMGN)
$166.3B
Gilead Sciences (GILD)
$141.3B
Vertex Pharmaceuticals (VRTX)
$122.5B
Bristol Myers Squibb (BMY)
$99.7B
CSL (CSLLY)
$85.2B
GSK (GSK)
$77.9B
Regeneron Pharmaceuticals (REGN)
$61.8B
Alnylam Pharmaceuticals (ALNY)
$42.5B
Argenex SE (ARGX)
$35.2B
BioNTech SE (BNTX)
$27.5B
Royalty Pharma (RPRX)
$20.2B
Insmed (INSM)
$19.6B
Biogen (BIIB)
$19.2B
Illumina (ILMN)
$16.6B
Genmab (GNMSF)
$14.9B
Genmab (GMAB)
$14.7B
Incyte (INCY)
$13.7B
Moderna (MRNA)
$13.4B
Exelixis (EXEL)
$12.4B
BioMarin Pharmaceutical (BMRN)
$11.4B
QIAGEN (QGEN)
$11.2B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.4B
Exact Sciences (EXAS)
$9.1B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Bio-Techne Corp (TECH)
$8.7B
Blueprint Medicines (BPMC)
$8.3B
Legend Biotech (LEGN)
$8.1B
Roivant Sciences (ROIV)
$7.7B